Current Progress and Research Trends in Ocular Oncology—2nd Edition
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: 1 April 2026 | Viewed by 38
Special Issue Editors
Interests: ocular oncology; primary tumor and metastasis; genetic and cellular heterogeneity; oncogenic pathways; cancer biology and immunology; molecular biomarkers; drug screening; 3D cell culture models; novel treatment options
Special Issues, Collections and Topics in MDPI journals
Interests: ocular oncology; primary tumor; uveal melanoma; conjunctival melanoma; metastatic risk; diagnostic strategies; innovative therapeutic options; electrochemotherapy; patient-derived xenograft models; vitreoretinal surgery
Special Issues, Collections and Topics in MDPI journals
Interests: ocular oncology; uveal melanoma; conjunctival melanoma; retinoblastoma; primary tumor; metastatic risk; clinic–pathologic analysis; diagnostic strategies; prognostic factors; therapeutic options; vitreoretinal surgery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We invite you to contribute to this Special Issue, which is the second edition of "Current Progress and Research Trends in Ocular Oncology" (https://www.mdpi.com/journal/cancers/special_issues/H4ZFP9OK92).
We invite you to contribute an original article or review in the field of ocular oncology, with a focus on uveal melanoma, conjunctival melanoma or retinoblastoma. Uveal melanoma and retinoblastoma, which cause blindness and even death, are the most common primary intraocular malignancies in adults and children, respectively. Conjunctival melanoma shares genetic and pathophysiological features with cutaneous melanomas and is distinct from uveal melanoma. Although our understanding of these ocular cancers has advanced over the last decade and local tumor control is mostly achievable, they remain malignancies with recurrence and no treatment for metastatic disease.
This Special Issue will highlight current progress and research trends in all aspects of ocular oncology, including oncogenic pathways and genetic and cellular heterogeneity, as well as cancer immunity that underlies the initiation, progression, recurrence and metastasis of ocular tumors. Basic science studies with translational aspects, as well as clinical trials, are strongly encouraged. Experts in the field are invited to contribute articles reviewing the latest perspectives on ocular cancer biology or diagnosis and therapy. This Special Issue reflects the wide range of efforts to advance the understanding and treatment of eye cancers.
Prof. Dr. Utta Berchner-Pfannschmidt
Dr. Miltiadis Fiorentzis
Prof. Dr. Nikolaos E. Bechrakis
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ocular oncology
- uveal melanoma
- conjunctival melanoma
- retinoblastoma
- primary tumor
- recurrence
- metastasis
- oncogenic pathways
- genetic and cellular heterogeneity
- cancer immunity
- diagnostic strategies
- therapeutic options
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
